España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
NeuroPace
NPCE
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$9.19
0
0.00%
After Hours: Nov 20, 4:01 PM EDT
Get Report
Comment
NeuroPace (NPCE) Forecast
News
Earnings
NeuroPace (NPCE) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for NeuroPace (NASDAQ:NPCE) Stock
NeuroPace Stock (NASDAQ: NPCE)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 13, 2024
Neuropace shares are trading higher after the...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on NeuroPace...
Benzinga Newsdesk
Tuesday, November 12, 2024
NeuroPace Q3 2024 GAAP EPS $(0.19) Beats $(0....
Benzinga Newsdesk
NeuroPace Raises FY2024 Sales Guidance from $...
Benzinga Newsdesk
Earnings Scheduled For November 12, 2024
Benzinga Insights
Monday, November 04, 2024
NueroPace Announced FDA Submission Of Its Thr...
Benzinga Newsdesk
Wednesday, August 14, 2024
Neuropace shares are trading lower. The compa...
Benzinga Newsdesk
Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on NeuroPace...
Benzinga Newsdesk
Tuesday, August 13, 2024
NeuroPace Lifts FY24 Revenue Guidance From $7...
Benzinga Newsdesk
NeuroPace Q2 2024 GAAP EPS $(0.26) Beats $(0....
Benzinga Newsdesk
Monday, July 15, 2024
Morgan Stanley Maintains Equal-Weight on Neur...
Benzinga Newsdesk
Thursday, May 09, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ne...
Benzinga Newsdesk
Wednesday, May 08, 2024
NeuroPace Maintains FY24 Revenue Guidance Of ...
Benzinga Newsdesk
NeuroPace Q1 2024 GAAP EPS $(0.32) Beats $(0....
Benzinga Newsdesk
Thursday, March 14, 2024
Wells Fargo Upgrades NeuroPace to Overweight,...
Benzinga Newsdesk
NeuroPace shares are trading higher after JP ...
Benzinga Newsdesk
Tuesday, March 12, 2024
The Latest Analyst Ratings For NeuroPace
Benzinga Insights
JP Morgan Maintains Overweight on NeuroPace, ...
Benzinga Newsdesk
Wednesday, March 06, 2024
Cantor Fitzgerald Maintains Overweight on Neu...
Benzinga Newsdesk
Morgan Stanley Maintains Equal-Weight on Neur...
Benzinga Newsdesk
Tuesday, March 05, 2024
NeuroPace Provides Full-year 2024 Revenue Gui...
Benzinga Newsdesk
Recap: NeuroPace Q4 Earnings
Benzinga Insights
NeuroPace Q4 2023 GAAP EPS $(0.23) Beats $(0....
Benzinga Newsdesk
Earnings Scheduled For March 5, 2024
Benzinga Insights
Monday, March 04, 2024
Earnings Preview: NeuroPace
Benzinga Insights
Thursday, February 22, 2024
A Glimpse Into The Expert Outlook On NeuroPace Through 4 Analysts
Benzinga Insights
Tuesday, January 30, 2024
NeuroPace Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Benzinga Insights
Leerink Partners Initiates Coverage On NeuroP...
Benzinga Newsdesk
Monday, January 08, 2024
NeuroPace Sees Prelim. Q4 Revenue $17.5M-$18M...
Benzinga Newsdesk
Wednesday, December 27, 2023
Breaking Down NeuroPace: 6 Analysts Share Their Views
Benzinga Insights
Lake Street Reiterates Buy on NeuroPace, Main...
Benzinga Newsdesk
Thursday, December 21, 2023
NeuroPace Disclosed The Completion Of The Pat...
Benzinga Newsdesk
Monday, December 04, 2023
NeuroPace Announces Strategic Collaboration T...
Benzinga Newsdesk
Neuropace Entered Collaboration With Rapport Therapeutics To Share Site Data For Rapport's Phase 2a Trial Of Their Gama 8 Receptor-associated Protein Compound.
Charles Gross
Expert Ratings for NeuroPace
Benzinga Insights
Morgan Stanley Maintains Equal-Weight on Neur...
Benzinga Newsdesk
Tuesday, November 14, 2023
Morgan Stanley Maintains Equal-Weight on Neur...
Benzinga Newsdesk
Friday, November 10, 2023
Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position
Vandana Singh
Expert Ratings for NeuroPace
Benzinga Insights
Cantor Fitzgerald Initiates Coverage On Neuro...
Benzinga Newsdesk
Tuesday, November 07, 2023
JP Morgan Maintains Overweight on NeuroPace, ...
Benzinga Newsdesk
Monday, November 06, 2023
NeuroPace Sees FY23 Revenue $62.5M-$63.5M Vs ...
Benzinga Newsdesk
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
NeuroPace Q3 EPS $(0.28) Beats $(0.41) Estima...
Benzinga Newsdesk
Earnings Scheduled For November 6, 2023
Benzinga Insights
Tuesday, October 17, 2023
NeuroPace Announces RNS System Enhancements D...
Benzinga Newsdesk
Thursday, October 05, 2023
NeuroPace 10% Owner Trades $75K In Company Stock
Benzinga Insights
Wednesday, October 04, 2023
Wells Fargo Maintains Equal-Weight on NeuroPa...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
